Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Polydex Pharmaceuticals Ltd. (OTC: POLXF).

Full DD Report for POLXF

You must become a subscriber to view this report.


Recent News from (OTC: POLXF)

Dextran Products Wins Awards for Water Conservation Efforts
TORONTO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited  (OTC MKTS:POLXF) (the “Company”) operating as Dextran Products , today announced it has received two awards for water conservation efforts. For several years, Management has been focusing on m...
Source: GlobeNewswire
Date: December, 10 2018 11:03
Polydex Pharmaceuticals reports Q2 results
Polydex Pharmaceuticals ( OTCPK:POLXF ): Q2 GAAP EPS of $0.02. More news on: Polydex Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: September, 19 2018 05:36
Polydex Reports Second Quarter Financial Results
TORONTO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited  (OTC/Pink:POLXF) (the “Company”) today announced financial results for the second quarter of the 2019 fiscal year. The three-month and six-month periods ending July 31, 2018 (together with compa...
Source: GlobeNewswire
Date: September, 19 2018 02:12
Polydex Pharmaceuticals reports Q1 results
Polydex Pharmaceuticals ( OTCPK:POLXF ): Q1 EPS of $0.03 More news on: Polydex Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: June, 15 2018 09:31
Polydex Pharmaceuticals Issues First Quarter Financial Results
TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2019, the period ending April 30, 2018.  All figures are reported in U.S. dollars.   &#x...
Source: GlobeNewswire
Date: June, 15 2018 09:15
CORRECTION: Polydex Pharmaceuticals Provides Year End Financial Report
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2018. All figures are reported in U.S. dollars. Due to management’s efforts, gross margins hav...
Source: GlobeNewswire
Date: May, 01 2018 15:26
Polydex Pharmaceuticals reports FY results
Polydex Pharmaceuticals ( OTCPK:POLXF ): FY EPS of $0.13 Revenue of $5.28M (-20.2% Y/Y) Press Release More news on: Polydex Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 01 2018 12:07
Polydex Pharmaceuticals Provides Year End Financial Report
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2018. All figures are reported in U.S. dollars. Gross margins have been maintained and, combined with...
Source: GlobeNewswire
Date: May, 01 2018 11:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-12N/A0.8215N/AN/A0
2018-12-11N/A0.8215N/AN/A0
2018-12-10N/A0.8215N/AN/A0
2018-12-07N/A0.8215N/AN/A0
2018-12-06N/A0.8215N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-273,1005,25059.0476Short
2018-11-131,5001,65290.7990Short
2018-11-123,5004,50077.7778Short
2018-11-076,7006,700100.0000Short
2018-11-053,6005,00072.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on POLXF.


About Polydex Pharmaceuticals Ltd. (OTC: POLXF)

Logo for Polydex Pharmaceuticals Ltd. (OTC: POLXF)

Polydex Pharmaceuticals Limited the Company is engaged in the research, development, manufacture and marketing of biotechnology based products for the veterinary and human pharmaceutical markets. This includes the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. Dextran, a generic name applied to certain synthetic compounds formed by bacterial growth on sucrose, is a polymer or giant molecule. The name Polydex combines the words polymer and dextran. The Company conducts its business operations through its two wholly owned subsidiaries/divisions. The manufacture and sale of Dextran and derivative products is conducted through Dextran Products, incorporated in Canada in Dextran Products ,and Chemdex Inc Chemdex which is incorporated in the state of Kansas, United States.FOR ADDITIONAL FINANCIAL INFORMATION AND NEWS, INCLUDING MORE RECENT QUARTERLY REPORTING, PLEASE VISIT OUR WEBSITE

 

Contact Information

 

 

Current Management

  • George G. Usher / CEO
  • Sharon Wardlaw / COO
  • John A. Luce / CFO
  • Jonathan Gardner / Securities Counsel
  • Linda Hughes / IR
  • George G. Usher / Chairman

Current Share Structure

  • Market Cap: $4,419,971 - 03/16/2018
  • Authorized: 10,000,000 - 01/31/2017
  • Issue and Outstanding: 3,399,978 - 01/31/2017
  • Float: 2,561,166 - 01/31/2017

 


Recent Filings from (OTC: POLXF)

Quarterly Report - Polydex Q3 2017 Financial Statements
Filing Type: Quarterly Report - Polydex Q3 2017 Financial StatementsFiling Source: OTC Markets
Filing Date: December, 15 2017
Quarterly Report - Polydex Q3 2017 Information and Disclosure Statement
Filing Type: Quarterly Report - Polydex Q3 2017 Information and Disclosure StatementFiling Source: OTC Markets
Filing Date: December, 15 2017
Quarterly Report - July 31 2017 Financial Statements
Filing Type: Quarterly Report - July 31 2017 Financial StatementsFiling Source: OTC Markets
Filing Date: September, 15 2017
Quarterly Report - Information and Disclosure Statement July 31 2017
Filing Type: Quarterly Report - Information and Disclosure Statement July 31 2017Filing Source: OTC Markets
Filing Date: September, 15 2017

 

 


Daily Technical Chart for (OTC: POLXF)

Daily Technical Chart for (OTC: POLXF)


Stay tuned for daily updates and more on (OTC: POLXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: POLXF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in POLXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of POLXF and does not buy, sell, or trade any shares of POLXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/